TAG1 and NRG PALLAS Collaborate on Lead-212 Supply Expansion
In a significant move for the medical isotope industry, TAG1 Inc. and NRG PALLAS B.V. have signed a Letter of Intent (LOI) to enhance the supply of Lead-212 (Pb-212) for cancer therapies in Europe. This innovative partnership aims to tackle the supply challenges that plague the healthcare sector, particularly in the realm of advanced cancer treatments.
Located in St. Louis, TAG1 Inc. is celebrated as a primary supplier of medical isotopes, while NRG PALLAS B.V. stands out as a global heavyweight in nuclear solutions. The collaboration will harness TAG1's unique portable Lead-212 generator alongside NRG PALLAS' exceptional Radium-224 production capabilities, thus paving a seamless path for delivering critical isotopes to the medical community.
Advancing Cancer Therapy Development
This strategic alliance intends to provide both pre-clinical and clinical quantities of Lead-212, enabling cancer innovators and institutions to develop next-generation therapeutic solutions. This partnership is particularly pivotal for pioneering therapy firms as well as hospital-based oncology programs catering to both adult and pediatric patients.
Sumit Verma, President and CEO of TAG1, emphasized the significance of this partnership, stating, "This milestone represents an important step in finding new cures for cancer. By combining NRG PALLAS' experience and our innovative generator, we believe we can accelerate the development of new Lead-212-based therapeutics for patients."
On the other side, Maurits Wolleswinkel, CEO of NRG PALLAS, echoed this sentiment by reflecting on the company's commitment to transforming ambitions into actionable results. He stated, "By joining forces with TAG1, we not only take a significant leap towards positioning NRG PALLAS as a leading supplier of Lead-212 in Europe but also move closer to realizing the vision of the Lead4Life program for patients."
Lead4Life: A New Era in Radiopharmaceuticals
The Lead4Life initiative, which recently launched in the Netherlands, is a groundbreaking public-private partnership focused on fostering the development of Lead-212-based radiopharmaceuticals. The emphasis on enhancing production and supply chain dynamics reflects a robust strategic direction that TAG1 and NRG PALLAS are eager to contribute to. Their collective prowess is likely to accelerate the transition from laboratory discoveries to effective patient treatments within this expansive framework.
About TAG1 Inc.
TAG1 Inc. is renowned for its pioneering role in the medical isotope industry, specializing in the production of Lead-212 (Pb-212) for Targeted Alpha Therapies (TATs). The company’s innovative generator is designed to unlock Lead-212 supply for essential pre-clinical and clinical trials of targeted alpha therapies. TAG1's mission focuses on improving cancer treatment through advanced nuclear medicine and contributing significantly to the radiopharmaceutical supply chain. More about TAG1 can be found at
TAG1 Inc..
About NRG PALLAS
NRG PALLAS serves as a leading entity in the domain of nuclear solutions, particularly in producing medical isotopes and advancing nuclear technologies. They supply vital medical isotopes used in diagnosing and treating life-threatening diseases daily, caring for over 30,000 patients dependent on these critical supplies. Additionally, NRG PALLAS is currently engaged in constructing a new reactor, the PALLAS reactor, ensuring the future security of medical isotope supply and nuclear research. Learn more about NRG PALLAS at
NRG PALLAS.
This collaboration marks a pivotal step in enhancing the landscape of cancer therapy, offering hope for innovative treatments that utilize Lead-212, and signifies the beginning of a promising journey for TAG1 and NRG PALLAS in the medical isotope market.